Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2011; 136(49): 2560-2561
DOI: 10.1055/s-0031-1292831
DOI: 10.1055/s-0031-1292831
Kommentar | Commentary
Leitlinien
Wer schützt Ärzte und Patienten vor Leitlinien?
Who protects physicians and patients from guidelines?Further Information
Publication History
19 October 2011
28 October 2011
Publication Date:
30 November 2011 (online)
-
Literatur
- 1 European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
- 2 European Medicines Agency (EMA). European Medicines Agency recommends restricting use of Multaq. http://www.ifap.de Letzter Zugriff: 9.11.2011
- 3 Philippin Y. Multaq: vers la fin du remboursement. http://www.liberation.fr Letzter Zugriff: 9.11.2011
- 4 Sanofi Aventis. Sanofi provides Multaq® Phase IIIb PALLAS Trial update. http://en.sanofi.com Letzter Zugriff: 9.11.2011
- 5 Serebruany VL.. Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?. Cardiology 2010; 117: 280-283
- 6 Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555